ARIA

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

Retrieved on: 
torsdag, maj 2, 2024
Cancer, ARIA, Radiation, EDGE, Siemens Healthineers, Medical examiner, Radiation therapy, Patient, Acquisition, PALO, RT, Standard of care, Health, Note, Medical imaging

With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.

Key Points: 
  • With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.
  • "As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian.
  • Varian is committed to generating evidence that can help improve patient outcomes and expand access to care.
  • VARIAN, HYPERSIGHT, ETHOS, HALCYON, EDGE, TRUEBEAM, ARIA CORE, and IDENTIFY are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

Retrieved on: 
torsdag, maj 2, 2024
Cancer, ARIA, Radiation, EDGE, Siemens Healthineers, Medical examiner, Radiation therapy, Patient, Acquisition, PALO, RT, Standard of care, Health, Note, Medical imaging

With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.

Key Points: 
  • With over 24 million new cancer cases expected by 2030, accessible, high-quality cancer treatment is crucial to improving patient outcomes1.
  • "As part of Siemens Healthineers, Varian is in a unique position to develop cutting-edge products and solutions that bridge the care gap globally," remarked Arthur Kaindl, Head of Varian.
  • Varian is committed to generating evidence that can help improve patient outcomes and expand access to care.
  • VARIAN, HYPERSIGHT, ETHOS, HALCYON, EDGE, TRUEBEAM, ARIA CORE, and IDENTIFY are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

Retrieved on: 
måndag, april 22, 2024
Amyloid, Alzheimer's disease, Jort, University, MCI, Inflammation, Oxidative stress, ARIA, News, Research, Neuroinflammation, Cognition, Doctor of Philosophy, ADAS, START, KOL, Patient, SHINE, Perception, Neuron, Antibody, Therapy, Plaque, Cerebrospinal fluid

“The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .

Key Points: 
  • “The KOL roundtable we conducted featured a panel of Alzheimer’s disease expert clinicians and researchers who highlighted the need to find Alzheimer’s disease treatments that are less burdensome for patients and their care partners,” said Lisa Ricciardi, Cognition’s president and CEO .
  • The SHINE study enrolled participants in the U.S. and several countries in Europe including The Netherlands.
  • Dr. Vijverberg reviewed the design of the SHINE study and the results of the preliminary analysis of the first 24 patients who finished six months of treatment.
  • An archive of the KOL roundtable discussion is available on the News & Events page of the Investors section of the Cognition website or may be accessed directly at the following URL: https://lifescievents.com/event/cognition/ .

Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions

Retrieved on: 
tisdag, april 23, 2024
Medical Devices, Health, Neurology, Health Technology, Clinical Trials, Radiology, FDA, Brain, International Society, Amyloid-related imaging abnormalities, ARIA, Abstract, Conference, CARE, Patient, Magnetic resonance, Observational study, Physician, Multiple sclerosis, Hyperfine structure, Biomarker, Medical imaging

These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).

Key Points: 
  • These seventeen abstracts span a wide variety of use cases, including two that highlight the utility of brain images acquired with the ultra-low-field Swoop® Portable MR Imaging® system to aid physicians screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases, including Alzheimer’s and multiple sclerosis (MS).
  • Conference attendees can learn more during these select presentations:
    “These abstracts are very encouraging.
  • Earlier this month, the company announced that the first patients have been scanned in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study

Retrieved on: 
onsdag, april 17, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Brain, Patient, Bleeding, Amyloid-related imaging abnormalities, Mass, ARIA, Workflow, Dementia, CARE, DRS, Radiology, Observational study, Physician, PMR, MRI, Multimedia, Hyperfine structure, Mass General Brigham, Medical imaging

Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.

Key Points: 
  • Patients with Alzheimer’s can now be treated with amyloid-targeting therapy, which reduces the amyloid plaque burden in the brain.
  • Teresa Gomez-Isla and W. Taylor Kimberly, will evaluate the Swoop® system to understand its potential role in the overall continuum of Alzheimer’s care.
  • “The newly approved amyloid-targeting therapy represents a major milestone in the global fight against Alzheimer’s, bringing hope of additional years of independent living to patients.
  • The required MRI scans to image brain abnormalities in patients receiving amyloid-targeting therapy present workflow challenges for patients and providers,” said Hyperfine, Inc. President and CEO Maria Sainz.

Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study

Retrieved on: 
måndag, april 15, 2024
Technology, Medical Devices, Neurology, Science, Consumer, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Software, Hardware, Radiology, Pharmaceutical, Data Management, Seniors, American Academy, ARIA, Disease, OLE, Patient, Cognito, RCT, Therapy, Frontiers

OVERTURE II enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.

Key Points: 
  • OVERTURE II enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.
  • There was no observed convergence of ADCS-ADL scores between early and delayed start groups in OVERTURE II.
  • No cases of ARIA or serious treatment-related adverse events were reported over 12 months in the 44-patient OVERTURE II study.
  • High device adherence (80%) was reported in OVERTURE II, which was comparable to that observed in OVERTURE I.

Raigmore Hospital in Scotland selects RayCare

Retrieved on: 
onsdag, april 17, 2024
Raigmore Hospital, Physics, ARIA, Radiation, Varian Medical Systems, RaySearch Laboratories, Communication, Automation, Documentation, Pressure, Patient, Nursing

STOCKHOLM, April 17, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®*.

Key Points: 
  • STOCKHOLM, April 17, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®*.
  • The radiotherapy center at Raigmore Hospital is the northernmost center for radiotherapy in the UK, treating close to 1,000 patients per year.
  • Steven Colligan, Head of radiotherapy physics, Raigmore Hospital, says: "We have used RayStation since 2016 and look forward to the introduction of RayCare to the department.
  • Johan Löf, founder and CEO, RaySearch, says: "Our installed base of RayCare customers is steadily increasing and I am happy to welcome Raigmore Hospital as a new RayCare customer.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
fredag, april 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Top 10 Best Practices for Website Accessibility Design and Development from a Leading Design Agency in the SF Bay Area

Retrieved on: 
onsdag, april 10, 2024
Education, Paratriathlon, Mac, ARIA, Smash, Disability, EMS, Semantics, Accessibility, Adobe, Conference, UC, WordPress, HTML, Stanford University, UCSF, Eye, XD, Rems, University of California, Berkeley, Multimedia, AA, Government, WCAG, Online shopping

BERKELEY, Calif., April 10, 2024 /PRNewswire-PRWeb/ -- Have you ever turned on the speech reader on your Mac and closed your eyes while navigating a website? It's a powerful test to learn how visually impaired people might experience your content.

Key Points: 
  • With the evolving landscape of digital content, it's essential for us as designers to stay up-to-date with the latest accessibility standards and best practices.
  • Many of these guidelines are considered best practices in website design and development; a few, however, are easy to overlook.
  • Alt text is an essential part of website accessibility, as it describes the content of images to visually impaired users.
  • Some of us from P6 enjoyed the Smashing SF Conference which had several sessions on accessibility, front-end design, boosting web performance, and more.

Canon Announces 27x Portable Broadcast Zoom Lens and Next-Generation Digital Drive Unit

Retrieved on: 
tisdag, april 9, 2024
Illumination, Sport, Electronic News, NAB, Camera, News, ENG, ARIA, Lens

The CJ27ex7.3B, Canon’s first 2/3” portable lens with a class leading [i] 27x optical zoom, expands and strengthens the company’s extensive broadcast lens lineup.

Key Points: 
  • The CJ27ex7.3B, Canon’s first 2/3” portable lens with a class leading [i] 27x optical zoom, expands and strengthens the company’s extensive broadcast lens lineup.
  • The new lens, with superb optical performance, is classified as a UHDxs lens, Canon’s highest image quality rating for broadcast optics.
  • The 27x zoom ratio, typically only available in 2/3” box lenses, is now offered in a portable lens with the introduction of the CJ27ex7.3B.
  • To learn more about Canon broadcast lenses, please contact your Canon broadcast representative or visit www.usa.canon.com .